Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654030 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Edward Hirschowitz.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00654030: Completed Phase 2 study, sponsored by Edward Hirschowitz.
NCT00654030 is a Phase 2 study that has completed, run by Edward Hirschowitz. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00654030, a Phase 2 study, has completed, sponsored by Edward Hirschowitz.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.
Primary Outcome
The endpoint is immunologic response measured by IFN-ELISPOT. It will be reported as the percent of patients responding to vaccine (\>2 Standard Deviation increase from baseline levels pre-vaccine). The number of individuals responding (\> 2 SD change from baseline vaccine) will provide an approximation of biologic efficacy of the vaccine.
Interventions
- DRUG 1650-G Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00654030 record still lists
NCT00654030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which 1650-G Vaccine is the first listed.
NCT00654030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00654030 about?
NCT00654030 is a clinical study titled "Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer". Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of in...
What is the current status of trial NCT00654030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00654030?
The interventions under investigation include: 1650-G Vaccine (DRUG).
Who is sponsoring clinical trial NCT00654030?
This trial is sponsored by Edward Hirschowitz, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00654030's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia